JP2021501581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501581A5 JP2021501581A5 JP2020524267A JP2020524267A JP2021501581A5 JP 2021501581 A5 JP2021501581 A5 JP 2021501581A5 JP 2020524267 A JP2020524267 A JP 2020524267A JP 2020524267 A JP2020524267 A JP 2020524267A JP 2021501581 A5 JP2021501581 A5 JP 2021501581A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- polypeptide
- gene locus
- sequence encoding
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 20
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 102100035233 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023150855A JP2024009805A (ja) | 2017-10-30 | 2023-09-19 | 初代細胞の遺伝子編集 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579113P | 2017-10-30 | 2017-10-30 | |
| US201762579114P | 2017-10-30 | 2017-10-30 | |
| US62/579,114 | 2017-10-30 | ||
| US62/579,113 | 2017-10-30 | ||
| PCT/US2018/058230 WO2019089610A1 (en) | 2017-10-30 | 2018-10-30 | Primary cell gene editing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150855A Division JP2024009805A (ja) | 2017-10-30 | 2023-09-19 | 初代細胞の遺伝子編集 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501581A JP2021501581A (ja) | 2021-01-21 |
| JP2021501581A5 true JP2021501581A5 (enExample) | 2021-12-09 |
| JP7397791B2 JP7397791B2 (ja) | 2023-12-13 |
Family
ID=66332290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524267A Active JP7397791B2 (ja) | 2017-10-30 | 2018-10-30 | 初代細胞の遺伝子編集 |
| JP2023150855A Pending JP2024009805A (ja) | 2017-10-30 | 2023-09-19 | 初代細胞の遺伝子編集 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150855A Pending JP2024009805A (ja) | 2017-10-30 | 2023-09-19 | 初代細胞の遺伝子編集 |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US10584357B2 (enExample) |
| EP (1) | EP3703712A4 (enExample) |
| JP (2) | JP7397791B2 (enExample) |
| CN (2) | CN117904055A (enExample) |
| AU (1) | AU2018357861B2 (enExample) |
| BR (1) | BR112020008704A2 (enExample) |
| CA (1) | CA3081320A1 (enExample) |
| IL (1) | IL274351B2 (enExample) |
| MX (1) | MX2020004541A (enExample) |
| RU (1) | RU2020116585A (enExample) |
| SG (1) | SG11202004026QA (enExample) |
| TW (1) | TWI716758B (enExample) |
| WO (1) | WO2019089610A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| KR102720855B1 (ko) | 2017-06-15 | 2024-10-25 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 비-바이러스 dna 삽입 |
| KR102503130B1 (ko) * | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| MX2020004541A (es) * | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
| SG11202009761YA (en) | 2018-04-02 | 2020-10-29 | Pact Pharma Inc | Peptide-mhc compacts |
| AU2019362879A1 (en) * | 2018-10-16 | 2021-05-27 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| AU2020264484A1 (en) | 2019-05-01 | 2021-11-04 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy |
| EP4010463A4 (en) * | 2019-08-05 | 2024-05-08 | Cartherics Pty. Ltd. | IMMUNE CELLS EXPRESSING MODIFIED CELL RECEPTORS AND METHOD FOR THE PRODUCTION |
| EP3999651A4 (en) | 2019-08-26 | 2023-07-26 | PACT Pharma, Inc. | METHOD OF EXECUTING GUIDE-SEQ ON PRIMARY HUMAN T-CELLS |
| TW202128196A (zh) * | 2019-10-08 | 2021-08-01 | 美商Ｐａｃｔ製藥公司 | 使用基因改造之自體ｔ細胞免疫療法之治療方法 |
| WO2021072218A1 (en) * | 2019-10-10 | 2021-04-15 | Pact Pharma, Inc. | Method of treating immunotherapy non-responders with an autologous cell therapy |
| CA3171369A1 (en) * | 2020-02-28 | 2021-09-02 | Wisconsin Alumni Research Foundation | Nonviral generation of genome edited chimeric antigen receptor t cells |
| CA3174943A1 (en) * | 2020-04-24 | 2021-10-28 | Kyle JACOBY | Methods of determining gene editing efficiencies in cells |
| WO2021252898A1 (en) * | 2020-06-12 | 2021-12-16 | Pact Pharma, Inc. | Compositions and methods of manufacturing autologous t cell therapies |
| IL300994A (en) * | 2020-08-28 | 2023-04-01 | Arsenal Biosciences Inc | Transgenic immune cells with priming receptors |
| AU2021368557A1 (en) * | 2020-10-27 | 2023-06-08 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| KR20230160885A (ko) * | 2021-03-24 | 2023-11-24 | 제넨테크, 인크. | T 림프구에서 효율적인 tcr 유전자 편집 |
| CN115867645A (zh) * | 2021-05-18 | 2023-03-28 | 赛斯尔擎生物技术（上海）有限公司 | 修饰细胞的方法 |
| KR20240021216A (ko) | 2021-06-11 | 2024-02-16 | 팩트 파마, 인크. | 세포 생성물을 감정하는 방법 |
| AU2024228388A1 (en) | 2023-02-27 | 2025-10-02 | Adaptive Biotechnologies Corp. | Therapeutic t cell receptors targeting kras g12d |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
| US9540657B2 (en) * | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| EP2975942B1 (en) * | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| EP4427809A3 (en) | 2014-10-31 | 2024-12-04 | The Trustees of The University of Pennsylvania | Altering gene expression in car-t cells and uses thereof |
| US20190030071A1 (en) * | 2014-11-03 | 2019-01-31 | IMMURES S.r.I. | T cell receptors |
| AU2016333886B2 (en) * | 2015-10-05 | 2020-10-08 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| EP4108255A1 (en) * | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| AU2017230011A1 (en) | 2016-03-11 | 2018-09-27 | 2Seventy Bio, Inc. | Genome edited immune effector cells |
| KR102503130B1 (ko) | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| MX2020004541A (es) * | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
-
2018
- 2018-10-30 MX MX2020004541A patent/MX2020004541A/es unknown
- 2018-10-30 SG SG11202004026QA patent/SG11202004026QA/en unknown
- 2018-10-30 BR BR112020008704-1A patent/BR112020008704A2/pt not_active Application Discontinuation
- 2018-10-30 RU RU2020116585A patent/RU2020116585A/ru unknown
- 2018-10-30 JP JP2020524267A patent/JP7397791B2/ja active Active
- 2018-10-30 CA CA3081320A patent/CA3081320A1/en active Pending
- 2018-10-30 WO PCT/US2018/058230 patent/WO2019089610A1/en not_active Ceased
- 2018-10-30 IL IL274351A patent/IL274351B2/en unknown
- 2018-10-30 CN CN202410054719.7A patent/CN117904055A/zh active Pending
- 2018-10-30 EP EP18872062.7A patent/EP3703712A4/en active Pending
- 2018-10-30 CN CN201880085053.4A patent/CN111918659B/zh active Active
- 2018-10-30 AU AU2018357861A patent/AU2018357861B2/en active Active
- 2018-10-30 TW TW107138453A patent/TWI716758B/zh active
-
2019
- 2019-08-27 US US16/552,714 patent/US10584357B2/en active Active
- 2019-08-27 US US16/552,786 patent/US10550406B2/en active Active
-
2020
- 2020-02-05 US US16/782,815 patent/US10676758B1/en active Active
- 2020-02-05 US US16/782,450 patent/US10711283B2/en active Active
- 2020-06-04 US US16/893,166 patent/US20200299730A1/en not_active Abandoned
-
2021
- 2021-08-12 US US17/400,974 patent/US20210395783A1/en not_active Abandoned
-
2023
- 2023-09-19 JP JP2023150855A patent/JP2024009805A/ja active Pending
-
2025
- 2025-04-25 US US19/189,452 patent/US20250250587A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501581A5 (enExample) | ||
| ES2848478T3 (es) | Receptores quiméricos para antígenos y usos de estos | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2018138049A5 (enExample) | ||
| RU2020116585A (ru) | Редактирование гена первичных клеток | |
| JP2017538401A5 (enExample) | ||
| EP2570429A3 (en) | Peptide vaccines with Seq ID No: 48, 41, 44, 46 or 78 for cancers expressing tumor-associated antigens | |
| UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
| JP2017018125A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| WO2012159006A8 (en) | Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof | |
| JP2020501550A5 (enExample) | ||
| JP2014508510A5 (enExample) | ||
| WO2012172277A4 (en) | Simian adenovirus and hybrid adenoviral vectors | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| MX362028B (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
| MX2018009225A (es) | Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. | |
| JP2009525052A5 (enExample) | ||
| WO2017190684A1 (zh) | 白细胞介素组合及其用途 | |
| JP2017513502A5 (enExample) | ||
| JP2017536337A5 (enExample) | ||
| JP2019500414A5 (enExample) | ||
| US11932679B2 (en) | Agent for restoring visual function or agent for preventing deterioration in visual function | |
| JP2015524403A5 (enExample) | ||
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E |